Shamburg News · 8-K filed Oct 26, 2026, 6:02 AM EDT
Phathom Pharmaceuticals Discloses FDA Public Docket on VOQUEZNA Exclusivity Litigation
PHAT · Phathom Pharmaceuticals, Inc.
- Other event
- Materiality: high
On October 26, 2026, Phathom Pharmaceuticals announced that the FDA established a public docket (No. FDA-2026-N-13038) to solicit comment on issues raised by an ANDA filer, BDR Pharmaceuticals, in litigation challenging FDA's June 6, 2025 decision granting Phathom's Citizen Petition recognizing 10 years of NCE exclusivity for VOQUEZNA through May 3, 2032. Public comments are due November 23, 2026. Phathom stated it believes the FDA reached the right decision and will defend the exclusivity in comments and any court proceeding; a second purported ANDA filer has also indicated it intends to seek consolidation with the BDR case.
Source: SEC EDGAR, Form 8-K, Item 8.01, accession 0001193125-26-430977.
Written from the filing by Shamburg Markets. Figures are as reported by the company.